US 6303790

I'll search for this specific patent and any related litigation.

US Patent 6,303,790 — Analyst Summary

Important caveat on method: I could not directly query the USPTO Patent Public Search or the CAFC docket system through the tools available here; the results below come from web search and the authoritative full-text patent record supplied. A search for "6303790" in a litigation context returned only an unrelated Brazilian industrial-design registration "DI 6303790-4" (INPI Brazil) — a different identifier and jurisdiction, not the US patent. I found no CAFC 2026 docket, appeal, or district-court case naming US 6,303,790. Treat the absence of litigation as "not found," not as confirmation that none exists.

Bibliographic data (literal)

Abstract (as written)

"A process is described for preparing certain 4-alkyl- or 4-aryl-pyridine derivatives."

Technical field

A synthetic process for making 4-alkyl/4-aryl pyridine derivatives (formula I), which the specification states are antagonists of the Neurokinin 1 (NK-1, substance P) receptor, useful for CNS indications such as depression, anxiety, and emesis.

Cited prior art (of record)

• EP 0235663 A1 — Warner-Lambert, substituted tetrahydro-3-pyridine-carboxylic acid/ester/amide cholinergic agents
• EP 1035115 A1 — F. Hoffmann-La Roche AG, 4-phenylpyridine derivatives as NK-1 antagonists
• Non-patent: W. Schlecker et al., Tetrahedron vol. 51, No. 35 (1995) pp. 9531–9542

Plain-language overview of the independent claim (claim 1)

The patent has one independent claim (claim 1); claims 2–14 all depend on it.

Claim 1 is a process claim for preparing a compound of formula I (a 4-substituted pyridine bearing an R¹ group at the 4-position, e.g., o-tolyl; an amide/carboxamide or amino-carboxamide side chain at the 3-position via linker X; and optionally a cyclic amine or other R⁴ group at the 2-position) and its pharmaceutically acceptable acid-addition salts. The process has these stages:

• Step (a): React a pyridine starting material (formula IV-1, where A is either a halogen R or the group R⁴) with a Grignard reagent R¹MgHal (formula V) — giving a mixture of dihydro-pyridine intermediates X-1 and XI-1;
  • or step (a′): React IV-1 (where A is halogen) with the Grignard reagent V and with HR⁴ (formula VII) in a single reaction step — giving intermediate VI.
• Step (b): Oxidize the resulting dihydro intermediate (X-1, XI-1, or VI) with an oxidizing agent to aromatize it into pyridine VIII.
• Step (c): React VIII with a halide reagent (IX) to give formula I where X is –C(O)N(R⁵)– (i.e., a nicotinamide);
  • or step (c′), used when X is –N(R⁵)C(O)–:
    • i) react VIII with IX to give XIII;
    • ii) convert XIII into XIV or XV (involving a Hofmann rearrangement to install the amino substituent, per dependent claim 7);
    • iii) transform XIV or XV into XVI where R⁵ is methyl; and
    • iv) react XVI with an acylating compound to give formula I where X is –N(R⁵)C(O)–.

The inventive point (per the specification's "DETAILED DESCRIPTION"): the R¹ group is introduced at the pyridine 4-position by a 1,4-addition that requires no activation of the pyridine ring at that position or on the nitrogen — described as "surprising" and "unexpected" relative to the known routes (schemes 1–2, EP 1 035 115) where an activating halogen (bromo/iodo) is needed.

Dependent claims narrow the process to specific conditions/reagents:

• 2: step (a) solvent = THF
• 3: step (b) oxidant list (Mn(OAc)₃, Cu(OAc)₂, I₂, Br₂, NBS, Pd/C, Pt/C, DDQ, o-chloranil, H₂O₂-urea, Na₂CO₃–H₂O₂, MnO₂, KMnO₄, RuCl₂(PPh₃)₃, ceric ammonium nitrate, HNO₃, S)
• 4: step (c) in THF with potassium bis(trimethylsilyl)amide
• 5: product = N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-6-(4-methyl-piperazin-1-yl)-4-o-tolyl-nicotinamide
• 6: step (c′i) with H₂SO₄ + AcOH or methanesulfonic acid
• 7: amino group introduced via Hofmann rearrangement
• 8–10: step (c′iii) conditions (alkyl orthoformate + catalytic acid; trimethyl orthoformate/TFA; reducing agents LiAlH₄, NaBH₄, BH₃-THF, Red-Al®)
• 11: reduction from formula XV using LiAlH₄ or Red-Al®
• 12: step (c′iv) in presence of a tertiary amine
• 13: product = 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
• 14: further step — reacting formula XII with formula VII to give formula VIII

Worked examples (8)

Examples 1–8 give full preparative detail, including Example 1 (the bis-trifluoromethyl-benzyl nicotinamide), Example 2 (methyl-[6-(4-methyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-amine), Example 4 (2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide), and Examples 6–8 (6-methyl, 4-isopropyl, and 4-(p-fluorophenyl) variants).

Family / foreign counterparts

EP 1103546 B1, JP 3403164 B2, KR 100371121 B1, CN 1176908 C, CA 2326815 C, DE 60006054 T2, DK 1103546 T3, ES 2208206 T3, AT 252559 T1, JO 2252 B1, MX PA00011670 A.

Uncertainty notes: (1) I did not obtain a live USPTO file-wrapper or Fee/Reassignment record beyond what the supplied full text and public indexing show — reassignment data should be verified directly at USPTO PatentCenter/Assignment. (2) No CAFC or district-court activity for this patent was found in the available searches; this is a negative search result, not an authoritative all-courts clearance. (3) The formula images in claim 1 are partially garbled in the OCR source (e.g., "A denotes R or R⁴"), so reagent-level details should be confirmed against the original patent drawings at patents.google.com/patent/US6303790B1/en.

I'll research litigation involving US patent 6303790. Let me run several targeted searches.

The initial searches pulled in unrelated "379" documents. Let me refine with more specific queries.

Let me search more specifically, including litigation databases and the patent's family.

Litigation Search Report — U.S. Patent No. 6,303,790 ("Process for the preparation of pyridine derivatives")

Bottom line

I found no litigation — district court, ITC, or Federal Circuit — involving U.S. Patent No. 6,303,790. Every litigation-side hit my searches returned concerned different patents, and I was unable to attribute a single case to this patent number. I am reporting this as a negative finding rather than asserting the patent was never litigated, because my searches had coverage limits (see caveats below).

What I searched and what came back

Why this is plausible for this specific patent

Several characteristics of US 6,303,790 make it a poor candidate for reported litigation:

1. It is a process patent, not a composition-of-matter or method-of-treatment patent. The claims are directed to a synthetic route for making 4-alkyl-/4-aryl-pyridine derivatives (the netupitant scaffold), specifically: (a) a 1,4-addition of an R¹‑magnesium halide to a pyridine ring without prior activation, (b) oxidation of the resulting dihydro intermediate, and (c) amide/amine coupling steps. Process patents are generally not listed in the FDA Orange Book and therefore are not the patents asserted in Hatch‑Waxman paragraph IV / ANDA suits — which is exactly what the Helsinn netupitant litigation is.
2. It expired. The patent's expiry is recorded as the anticipated expiration of 2020‑11‑20, with legal status "Expired – Lifetime." Any enforcement window closed years ago.
3. Assignment history shows it was assigned from F. Hoffmann‑La Roche AG to Hoffmann‑La Roche Inc. (recorded 2001‑04‑13), and the netupitant franchise was later developed/commercialized by Helsinn. The family's later, litigated patents (the Akynzeo patent estate) are the ones that carried the enforcement activity.

Family context (for completeness — not litigation)

• The U.S. case is the same family as EP 1103546 B1 (granted 2003‑10‑22) and has counterparts in CN, JP (JP3403164B2), KR (KR100371121B1), CA (CA2326815C), and others.
• It cites only two prior-art references: EP 0235663 A1 (Warner‑Lambert) and EP 1035115 A1 (F. Hoffmann‑La Roche), plus one non-patent citation (Schlecker et al., Tetrahedron 51(35):9531‑9542, 1995).
• It is cited by later Roche process patents (e.g., US 7,288,658 B2, "Process for preparation of pyridine derivatives"), which is citation activity, not litigation.

Caveats — please verify independently before relying on this

• I could not complete direct queries against the Unified Patents litigation caselist, PACER, or CourtListener's docket search for this exact number; those interfaces were not reachable within my search budget. My conclusion rests on general web search plus the sources above.
• Only the U.S. patent was searched. I did not systematically search foreign enforcement (e.g., European or Asian litigation on family members), which would not appear under this U.S. number anyway.
• Because the patent number "6303790" is easily confused with other "379" patents, several results I found were about different patents (the staples '379 patent; the Brazilian design registration). I have excluded those rather than folding them into the record.

Recommended verification steps

To close the gap on the sources I could not reach:

1. Unified Patents litigation portal — search the caselist by patent number 6303790.
2. PACER / CourtListener RECAP — full‑text search for "6,303,790" across all district courts (the number appears literally in complaints that assert it).
3. USPTO Patent Center / PTAB — confirm no IPR, PGR, or reexamination was filed against it (a review of the file wrapper would confirm).
4. Darts‑IP or Lex Machina — commercial litigation databases that index U.S. patent assertions by patent number.

If a case does exist and was not surfaced, it would most likely be a 2001–2020 era district court action by Hoffmann‑La Roche against a generic manufacturer over the netupitant synthesis route — but based on the evidence available to me, no such case is documented, and I cannot represent that any exists.

I'll start by verifying the structured-data baseline and probing for any PTAB activity the ODP may not have indexed.

The first pass surfaced unrelated '379 patents. Let me probe the patent's commercial embodiment (netupitant/Helsinn) and Roche litigation history for any IPR activity.

Those hits concern Helsinn's netupitant formulation/method patents, not the '790 process patent. Let me run targeted checks on the '790 patent itself.

Proceedings overview

Total AIA trial proceedings on US 6,303,790: zero. The USPTO Open Data Portal structured record supplied in this prompt returns no IPR, PGR, or CBM proceedings for this patent, and my independent searches (Google Patents litigation/PTAB links, drugpatentwatch PTAB listing for the netupitant/palonosetron franchise, and general "IPR + 6303790" queries) surfaced no petition, no institution decision, no Final Written Decision, and no Federal Circuit appeal naming US 6,303,790. Accordingly the breakdown is: active 0 / claims invalidated 0 / claims sustained 0 / settled 0 / institution denied 0.

Bottom-line defensive posture: the patent is completely unhardened and completely untested — every claim is a blank slate — but it is also expired as of 2020-11-20 (Google Patents "Anticipated expiration"; legal status "Expired - Lifetime"). That combination is unusual and cuts in the defendant's favor: there is no PTAB record to borrow from, but there is also no live patent term to enjoin. Any demand letter premised on ongoing infringement of this patent after 2020-11-20 is legally incoherent; the only conceivable exposure is past damages in the six years preceding service of a complaint (35 U.S.C. § 286).

⚠️ Landmine to avoid: web searches return multiple other "'379 patents" — a memory-controller patent with IPRs (IPR2025-00631-adjacent material, LaBerge/Bowater/Fujioka art) and a surgical-stapler patent (Green/Solyntjes art). Those snippets reference "the '379 patent" but are not US 6,303,790. Do not import their claim outcomes into this analysis. Likewise, the 2018–2020 ITC/Delaware campaign citing IPR2018-01247, -01248, -01254, IPR2019-00880, and IPR2019-01066 involves a different patent family and a different patent owner.

Proceedings

None. There are no proceedings to enumerate. For the record, per the task's requirement to state absence plainly:

• No Inter Partes Review
• No Post-Grant Review (and this patent could never have been PGR-eligible — it issued 2001-10-16, long before the AIA's 2013-03-16 PGR cutoff)
• No Covered Business Method review (and CBM would have been subject-matter-ineligible anyway — this is a chemical process claim, not a "financial product or service")

Verified against:

• USPTO Open Data Portal structured block (canonical, per this prompt): no AIA trial proceedings
• Google Patents "US6303790B1" page (https://patents.google.com/patent/US6303790/en): no PTAB trial entries; only prosecution citations (EP0235663A1; EP1035115A1) and a non-patent citation (Schlecker et al., Tetrahedron 51(35), 9531–9542 (1995))
• https://developer.uspto.gov/ptab-api — no matching patent number in returned data

Strategic summary

Claim status: all 14 claims UNTESTED — but the whole patent is time-barred by expiry. Nothing has been canceled and nothing has been affirmed. Claims 1–14 stand exactly as granted on 2001-10-16. That is a procedural blank slate, not a commercial one: under 35 U.S.C. § 154(a)(2), the 20-year term from the 2000-11-20 filing date ran to 2020-11-20, and Google's legal-status field confirms "Expired - Lifetime." The last maintenance-fee event I can retrieve is the 12-year payment on 2013-03-18, and no later fee events appear in the fetched record — worth confirming on USPTO Patent Center if the distinction between term expiry and fee lapse ever matters, but the "Expired - Lifetime" designation points to term expiry rather than mid-term lapse. Either way, there is no enforceable forward term.

Estoppel landscape: empty, and irrelevant. Because no IPR was ever instituted, no petitioner (or privy) is subject to the § 315(e)(2) estoppel bar. Every prior-art ground — § 102 and § 103, patents and printed publications alike — remains theoretically available in district court, as do grounds that IPR can never reach: § 112 written description/enablement, § 101, on-sale bar (§ 102(b) pre-AIA), public use, and prior knowledge. In practice, though, the only live invalidity question for an expired patent is whether it was invalid during the past-damages window; invalidity of an expired patent is a defense to past damages, not a route to prospective relief.

Pattern signals. US 6,303,790 is a Hoffmann-La Roche process patent (inventors Hilpert, Hoffmann-Emery, Rimmler, Rogers-Evans, Stahr, Waldmeier; original assignee Hoffmann La Roche Inc.). It is one of three Roche patents identified in Helsinn's own 2009 provisional as describing how to synthesize netupitant ("Methods of synthesizing netupitant are described in U.S. Patent Nos. 6,297,375, 6,479,483, and 6,303,790"). The netupitant IPR wave that actually happened — led by Azurity Pharmaceuticals in 2025 against Helsinn's later-generation patents (search results reference Azurity petitions filed 2025-05-01 against US 10,828,297, US 8,623,826, US 9,943,515, and US 9,186,357, with PTAB decisions dated 2025-11-19, and docket entries for IPR2025-00945 and IPR2025-00947) — pointedly does not include US 6,303,790. That is unsurprising: the '790 patent was already 20 years past filing and expired when that campaign was launched, so there was nothing to attack. No defensive aggregator (Unified Patents, RPX) appears anywhere in this patent's chain. No patent-owner PTAB appeal exists to analyze.

Recommended next steps

1. Say the quiet part plainly in any invalidity opinion: there is no PTAB activity on US 6,303,790 and therefore no FWD to cite. Do not represent to a court or client that any claim has been invalidated — none has.
2. Lead with expiration, not invalidity. Anchor on the 2020-11-20 expiration and § 286's six-year lookback. As of today's date (2026-09-30), that lookback reaches back only to roughly 2020-09-30 — a window of about seven weeks (2020-09-30 → 2020-11-20) in which infringement of this patent could even theoretically generate recoverable damages. Demand the plaintiff identify the specific accused acts falling in that window, and the specific claims read onto them.
3. If a plaintiff does assert it, pull the file wrapper from Patent Center and the European counterpart EP1103546B1 (B1 granted 2003-10-22; family members also JP3403164B2, KR100371121B1, CN1176908C, CA2326815C). I did not verify whether EP1103546B1 attracted an EPO opposition, and I won't speculate — but an EPO opposition would be the one place a claim-level validity record on this family might exist. Check EPO Register and Espacenet.
4. If you nonetheless want an AIA petition on the books (e.g., as estoppel-leverage in a parallel dispute), note that a petition against a 25-year-old expired patent faces meaningful discretionary-denial headwinds on "settled expectations"/patent-age grounds — the very issue framed in the pending Kahoot! cert petition (S. Ct. No. 25-308, challenging the Federal Circuit's denial of mandamus where the PTO refused institution based on patent age). Treat patent-age denial as a live risk, and note that an expired patent cannot be amended in an IPR, which moots much of the practical benefit.
5. Watch the Azurity/Helsinn netupitant IPRs for art transfer only. The references used against Helsinn's later patents — Bös (US 6,297,375), Hoffmann et al. (16 Bioorg. Med. Chem. Lett. 1362 (2006)), Herrstedt, Herrington, Hargreaves — are all relevant to netupitant chemistry and to the product made by this process. They are not prior art against the '790 process claims on their face (most post-date the 1999-11-29 priority date), but the Bös '375 patent and the Schlecker 1995 Tetrahedron paper cited on the '790 face are the natural starting points if you ever need a § 103 theory. Verify every reference's date against the 1999-11-29 priority date before relying on it.

Sources / links

• US6303790B1 (Google Patents): https://patents.google.com/patent/US6303790/en
• PTAB E2E (search by patent number): https://ptacts.uspto.gov/ptacts/public-informations/patent-informations
• PTAB Final Written Decisions portal: https://www.uspto.gov/patents/ptab/decisions
• CourtListener RECAP (for any future CAFC appeal): https://www.courtlistener.com/
• Family member EP1103546B1 (Espacenet): https://worldwide.espacenet.com/patent/search?q=EP1103546

Confidence note: I have high confidence that no AIA trial proceeding exists against US 6,303,790 — the ODP structured record is empty and no search surfaced one. I have moderate-to-high confidence on the 2020-11-20 expiration and the identified Azurity IPR numbers against other Helsinn patents (sourced from docket aggregator and petition PDFs, not from the ODP block in this prompt). I did not verify EPO opposition status for EP1103546B1 and am not asserting one exists.

I'll verify the assignment record and check for any post-issuance transfers before reconstructing the chain.

Let me check whether the netupitant patent family was ever transferred out of Roche (e.g., to Helsinn) and confirm there's no litigation on this patent.

Ownership & Assignment Analysis — US 6,303,790 B1

Patent: Process for the preparation of pyridine derivatives
App. No.: 09/716,538 · Filed: 2000-11-20 · Granted: 2001-10-16 · Priority: 1999-11-29 (EP 99123686)
Current status: Expired – Lifetime (anticipated expiration 2020-11-20)

Data-access note: I could not retrieve a live Assignment Center/PEDS record through the search tools available in this session (queries against the reel/frame numbers and the patent number returned no matching assignment record). The assignment facts below are taken from the Google Patents "Legal Events" / assignment abstract of the patent, which reproduces the USPTO-recorded reel/frame entries. Where a field was not recoverable (notably the correspondent of record), I say so rather than infer it.

Inventors

Employer is determinable because all six inventors executed an assignment to F. Hoffmann-La Roche AG (reel 011723/0662) eleven days before the application was filed — the standard employee-invention assignment for a corporate R&D team. These six are the process/preparation chemistry team; they are a distinct group from the compound-discovery inventors (e.g., Torsten Hoffmann, Michael Bös, Heinz Stadler, et al.) listed on the sibling netupitant compound patent, US 6,297,375 / EP 1,103,545.

Unusual-pattern check: Not determinable from the record and no evidence of the "mass-departure precedes fire-sale" pattern. The six inventors all assigned at once pre-filing and appear as a coherent Roche Basel chemistry group. I found no evidence that any of them left Roche on a timeline relevant to an NPE transfer.

Original assignee

Two Roche entities appear in the chain, and the face-of-patent assignee is the U.S. operating subsidiary:

• F. Hoffmann-La Roche AG — Swiss parent, Grenzacherstrasse, Basel. One of the largest research-based pharmaceutical companies in the world; operating (no bankruptcy, no dissolution). Took the inventors' assignment on 2000-11-08 and immediately assigned to its U.S. affiliate on 2000-11-10.
• Hoffmann-La Roche Inc. — U.S. subsidiary, New Jersey; the entity on the issued patent and the eventual record owner. Operating.

Product linkage: The patent is a process patent in the netupitant NK-1 antagonist family. Claim 13 recites 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide, the compound known as netupitant. Netupitant is the NK-1 active ingredient in AKYNZEO® (netupitant/palonosetron), approved by FDA in 2014 and marketed by Helsinn Healthcare SA — i.e., the claimed chemistry is embodied in a real commercial drug, though Roche itself does not market the finished product. Roche's own line of business is branded pharmaceuticals.

Status: Both Roche entities remain operating. The U.S. patent itself is expired (20-year term, no maintenance lapse shown — fees paid at years 4, 8, and 12).

Assignment timeline

Two recorded assignments, both recorded the same day, both internal to the Roche corporate family. There are no post-issuance assignments on this patent.

• 2000-11-08 (executed) / recorded 2001-04-13 — Reel 011723/0662

  • Conveyance: Assignment
  • Assignor: Hans Hilpert; Fabienne Hoffmann-Emery; Goesta Rimmler; Mark Rogers-Evans; Helmut Werner Stahr; Pius Waldmeier (jointly)
  • Assignee: F. Hoffmann-La Roche AG (Basel, Switzerland)
  • Correspondent: Not recoverable — the Assignment Center correspondent field was not exposed in any source I could access. I will not guess a name. (See signal 3 below; flagged as a data gap, not a finding.)
  • Context: Original employee-invention assignment executed ~12 days before the 2000-11-20 filing date — i.e., this is part of the original title chain, not a secondary transfer.

• 2000-11-10 (executed) / recorded 2001-04-13 — Reel 011723/0814

  • Conveyance: Assignment
  • Assignor: F. Hoffmann-La Roche AG
  • Assignee: Hoffmann-La Roche Inc. (New Jersey)
  • Correspondent: Not recoverable (same gap as above).
  • Context: Internal corporate reorg — transfer of the application from the Swiss parent to the U.S. operating subsidiary, standard practice so the U.S. affiliate holds U.S. patents. Recorded alongside the inventor assignment on the same reel (011723), consistent with a single filing of two papers on 2001-04-13.

Chain terminates here. No subsequent assignment, security interest, license recordation, merger, change-of-name, or release appears for US 6,303,790.

Non-assignment context worth noting (not an ownership transfer): Roche out-licensed the netupitant program to Helsinn Healthcare SA (announced 2005-06-02), and related Roche NK-1 filings were later moved to Helsinn in some jurisdictions — e.g., the EP register shows a transmission totale de propriété to Helsinn for the related EP 1,863,767 metabolite case (BOPI 2015-06). No such transfer is recorded against US 6,303,790; the U.S. record still shows Roche Inc. as owner. I am deliberately not treating a foreign-family transfer as a U.S. assignment of this patent.

Timeline diagram

timeline
    title Ownership of US 6303790
    1999 : Priority date EP 99123686
    2000 : Application filed 2000-11-20
         : Inventors assign to F Hoffmann La Roche AG
         : Roche AG assigns to Hoffmann La Roche Inc
    2001 : Both assignments recorded 2001-04-13
         : Patent granted 2001-10-16
    2005 : Roche licenses netupitant to Helsinn
    2014 : FDA approves AKYNZEO
    2020 : Patent term expires

NPE / troll-pattern signals

Near-miss worth flagging (not scored as a signal): Roche's 2005 out-license of netupitant to Helsinn is the kind of transaction that sometimes precedes a transfer-to-asserter. Here it did not: Helsinn is an operating drug developer/manufacturer holding the NDA for AKYNZEO, the patent record shows no assignment to Helsinn, and no assertion activity touches the '790 patent. This is a licensing-into-an-operating-company fact, not an NPE fact.

Verdict

Insufficient data — specifically, ownership never moved beyond the original corporate family, and there is no assertion activity on this patent.

Justification: the entire recorded chain is the two original pre-filing assignments — inventors → F. Hoffmann-La Roche AG (reel 011723/0662, executed 2000-11-08) and Roche AG → Hoffmann-La Roche Inc. (reel 011723/0814, executed 2000-11-10), both recorded 2001-04-13 — with zero post-issuance assignments, security interests, or licenses of record, and no litigation naming the patent. Under the rubric's own definition ("no records, or only the original assignment"), that lands in Insufficient data; substantively, the affirmative finding is the complete absence of any NPE-consistent signal, i.e., the patent stayed with a large operating pharmaceutical company and has now expired.

Verify at: USPTO Assignment Center — https://assignmentcenter.uspto.gov/ (search patent number 6303790; the legacy interface https://assignment.uspto.gov/patent/index.html surfaces the same records). When you pull the live record, please capture the correspondent of record for reels 011723/0662 and 011723/0814 — that is the one field I could not verify, and it is the field that would either confirm or close out signal 3.

I'll verify the patent record and research each cited prior-art reference.

Let me verify a few specific details on the cited references and the Warner-Lambert family.

Prior-Art Analysis for US Patent 6,303,790 B1

0. Scope note / method

I could not open a live USPTO Patent Public Search or PatentCenter file-wrapper view with the tools available here (the last two lookups returned no document-level results). Accordingly, the analysis below is grounded in (a) the authoritative full-text record of US 6,303,790 B1 and (b) public bibliographic records for each cited reference. Where I could not confirm a detail from a primary document, I say so explicitly. No contradiction was found between this and the earlier summary — the earlier citation list (EP 0 235 663 A1; EP 1 035 115 A1; Schlecker et al.) is confirmed and is extended here with dates and content.

Governing law: US 6,303,790 was filed 2000‑11‑20 and issued 2001‑10‑16, so pre‑AIA 35 U.S.C. § 102/§ 103 controls. Its effective date is the EP priority date 1999‑11‑29 (EP 99123686).

1. Confirmation of the record for 6303790 (literal)

Citations of record ("Patent Citations": 2; "Non-Patent Citations": 1):

1. EP 0 235 663 A1
2. EP 1 035 115 A1
3. W. Schlecker, A. Huth, E. Ottow, J. Mulzer, Tetrahedron 1995, 51(35), 9531–9542 (non-patent literature)

2. Reference-by-reference

2.1 EP 0 235 663 A1 — Warner-Lambert Company

Full citation: EP 0235663 A1, "Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents," Warner-Lambert Company. Application EP 87102216 A; priority US 83003586 (1986‑02‑18). Equivalent US publication: US 4,745,123 A (granted 1988‑05‑17). IPC C07D 211/78; C07D 413/12; C07D 409/04; A61K 31/455.

Publication / filing dates: filed 1987‑02‑17; published 1987‑09‑09.

Brief description: Discloses 1,2,3,6‑ and 1,2,5,6‑tetrahydropyridine‑3‑carboxylic acids, esters and amides of formula I having muscarinic (cholinergic) activity, useful for symptoms of senile cognitive decline. Position 3 bears an acid/ester/amide group — including –CONR′R″ where R′/R″ independently may be H or C1‑C4 alkyl, or together with N form pyrrolidinyl, piperidinyl, azepinyl, morpholinyl, thiomorpholinyl, piperazinyl or 4‑alkyl‑piperazinyl. Position 4 (R⁴) is C1‑C6 alkyl, C2‑C6 alkenyl, C3‑C8 cycloalkyl, 2‑/3‑thienyl, phenyl (optionally substituted) or phenyl‑(C1‑C6)alkyl. The preferred class is 4‑phenyl‑1,2,5,6‑tetrahydropyridine‑3‑carboxamides. The document also contains a Reaction Sequence and Examples describing how these compounds are made.

§ 102 relevance — claims potentially affected: None directly; claim 1 is not anticipated.

• EP 0 235 663 is a compound/composition patent. Its disclosed 4‑aryl‑tetrahydropyridine‑3‑carboxamides are structurally the dihydropyridine intermediates of claim 1 (formulae X‑1 / XI‑1, and the "4,5‑dihydro" species seen in Example 1(b) of US 6,303,790). The overlap is strongest with the step (a)/a′) substrate-plus-4‑aryl intermediate subject matter that feeds dependent claims 2–4, and with the amide/cyclic-amine substituents (morpholinyl, 4‑alkyl‑piperazinyl) recited in the R⁴ definition of formula I.
• However, EP 0 235 663 does not disclose (i) the 6‑substituted nicotinamide starting materials of formula IV‑1 in the claimed arrangement, (ii) the oxidation step (b) to the aromatic pyridine VIII, or (iii) either of the alternative final routes (c) or (c′) to formula I. A § 102 anticipation of claim 1 (or claims 2–14, all of which depend from it) requires all claimed steps in a single reference; that is absent here.
• Net effect: relevance is as (1) evidence of the state of the art for the 4‑aryl‑tetrahydropyridine‑3‑carboxamide core and (2) a possible § 103 secondary reference. No claim reads on it for anticipation. ⚠️ Unverified: whether the EP 0 235 663/US 4,745,123 Reaction Sequence itself employs a Grignard 1,4‑addition to a pyridine‑3‑carboxamide. If it does, its § 103 weight rises considerably; I could not retrieve the full experimental section to confirm.

2.2 EP 1 035 115 A1 — F. Hoffmann-La Roche AG

Full citation: EP 1035115 A1 (granted EP 1035115 B1; divisional EP 1394150 B1), "4‑Phenylpyridine derivatives and their use as NK‑1 receptor antagonists," F. Hoffmann-La Roche AG. Application EP 00102260.7.

Publication / filing dates: filed 2000‑02‑15; published 2000‑09‑13 (Bulletin 2000/37). Priorities: EP 99103504 (1999‑02‑24) and EP 99123689 (1999‑11‑29).

Brief description: Discloses the same 4‑(o‑tolyl)pyridine/nicotinamide and 2‑aryl‑isobutyramide compound class claimed as end products in US 6,303,790 (e.g., the R⁴/X Markush is materially the same: R⁴ = –N(R⁵)₂, –N(R⁵)(CH₂)ₙOH, –N(R⁵)C(O)R⁵, cyclic tertiary amines, etc.; X = –C(O)N(R⁵)– or –N(R⁵)C(O)–). It states these compounds are NK‑1 (substance P) antagonists and gives processes (schemes 1–3) for their preparation, including deprotonation with KHMDS and reaction of an amide/amine intermediate with an alkylating or acylating partner.

§ 102 relevance — claims potentially affected: None under § 102 as an EP publication; claim 1 is not anticipated.

• Date problem for § 102(a)/(b): EP 1 035 115 A1 was published 2000‑09‑13, i.e. after the 1999‑11‑29 effective date of US 6,303,790. As a printed publication it therefore does not qualify as § 102(a) or § 102(b) art against the priority date. (It is also not § 102(b) art against the 2000‑11‑20 filing date, being less than one year earlier.)
• What it does show: the applicant's own specification states the compounds "can be prepared by methods described in or analogous to those in EP 1035115, for example, by processes described in schemes 1 and 2," and identifies those schemes as the known, activated‑ring route in which "the introduction of the group R¹ … is carried out with an activated pyridine ring, wherein the activating group is a halogen atom, such as bromo or iodo." On the face of the US 6,303,790 specification, EP 1 035 115 therefore describes a different, halogen‑activated route, not the claimed "1,4‑addition without activation of the pyridine ring." It cannot anticipate claim 1 or claims 2–14.
• Potential collateral issues (not anticipation): (i) EP 1 035 115 shares priority day 1999‑11‑29 (EP 99123689) with this patent's EP 99123686 and is commonly owned/commonly invented at Roche — a double‑patenting/§ 103(c)‑type consideration, not § 102. (ii) If a US counterpart of EP 1 035 115 was filed before 1999‑11‑29 it could raise § 102(e) questions; on the available record its US/EP filings postdate that date, so no § 102(e) art is established. ⚠️ Unverified: the exact US filing date of the corresponding US family member.
• Sibling filings worth noting (not "citations," but the same family): EP 1 103 545 B1, priority 1999‑11‑29 ("2‑(3,5‑bis‑trifluoromethyl‑phenyl)‑N‑methyl‑N‑(6‑morpholin‑4‑yl‑4‑o‑tolyl‑pyridin‑3‑yl)‑isobutyramide" — the compound of claim 13), and EP 1 103 546 B1, the foreign counterpart of this patent.

2.3 Non‑patent literature — Schlecker, Huth, Ottow, Mulzer (1995) ⚠️ the materially dangerous reference

Full citation: W. Schlecker, A. Huth, E. Ottow, J. Mulzer, "Synthesis of 4‑Arylpyridines and Substituted β‑Carbolines via 1,4‑Grignard‑Addition to Pyridinecarboxamides," Tetrahedron 1995, 51(35), 9531–9542 (Schering AG Berlin / J.W. Goethe‑Universität Frankfurt). Received 15 Feb 1995; presented 28 Aug 1995.

Dates: published 1995 — more than one year before the 2000‑11‑20 filing date and before the 1999‑11‑29 priority date, so it is unambiguously § 102(b) prior art.

Brief description: Reports that 2,5‑pyridinedicarboxamides, 5‑bromo‑3‑pyridinecarboxamide and 3‑hydroxy‑2,5‑pyridinedicarboxamide undergo 1,4‑addition with Grignard reagents to give 2,4,5‑, 3,4,5‑ and 2,3,4,5‑substituted pyridines after oxidation with NCS or oxygen; the amide products are then converted to carbamates and cyclized to β‑carbolines.

§ 102 relevance — claims potentially affected: This is the closest prior art, but it does not fully anticipate claim 1.

• Direct overlap. Schlecker expressly discloses the two core steps of claim 1:
  • Step (a)/a′) — 1,4‑Grignard addition to a pyridinecarboxamide (i.e., to the nicotinamide‑type ring bearing a 3‑carboxamide, exactly the motif of formula IV‑1), and
  • Step (b) — oxidation of the resulting dihydropyridine to re‑aromatize it (NCS or O₂ are within the class of oxidants recited in dependent claim 3).
    This is also the chemistry embodied in the patent's own Examples 6–8 (e.g., N‑tert‑butyl‑6‑chloro‑nicotinamide + o‑tolylmagnesium chloride, then DDQ), and the amide→carbamate transformation in Schlecker prefigures dependent claim 14's amide‑to‑R⁴ conversion concept.
• Why it still does not anticipate claim 1. Claim 1 is a multi‑step process reciting both the Grignard/oxidation sequence and the subsequent transformation to formula I via step (c) (X = –C(O)N(R⁵)–, reductive alkylation of the nicotinamide nitrogen) or step (c′) (the Hofmann‑rearrangement route to the –N(R⁵)C(O)– linker, dependent claims 6–13). Schlecker stops at substituted pyridinecarboxamides/carbamates and β‑carbolines; it does not disclose the final amidation/alkylation to the NK‑1 antagonists of formula I, nor the Hofmann‑rearrangement sequence. Under § 102 all elements must appear in one reference, so claims 1–14 are not anticipated by Schlecker.
• Where the real exposure is: Schlecker is the primary § 103 reference against the inventive point the specification itself identifies — the assertion that introducing R¹ "occurs selectively in the 4‑position … without an activation of the pyridine ring," described in the patent as "surprising" and "unexpected." Because Schlecker already teaches 1,4‑Grignard addition to pyridinecarboxamides followed by oxidation, an obviousness/§ 103 attack on claim 1 is the live risk, not § 102 anticipation. (Note the patent does not claim a purity/selectivity limitation that would distinguish Schlecker on its face.)

3. Bottom line — which claims, if any, are anticipated under § 102

Conclusion: On the citations of record, no reference anticipates any claim of US 6,303,790 under 35 U.S.C. § 102. The patent's novelty position rests on the combination of the unactivated 1,4‑Grignard addition with the subsequent amidation/Hofmann‑rearrangement routes to the NK‑1 antagonists; the Schlecker 1995 paper comes closest but omits the final synthetic stages, making § 103 obviousness the material validity question rather than § 102 anticipation.

4. Explicit uncertainties

1. I could not retrieve the EP 0 235 663 A1 / US 4,745,123 Reaction Sequence and worked Examples; whether that document itself performs a Grignard 1,4‑addition on a pyridine‑3‑carboxamide is unverified and would materially change its § 103 weight.
2. I could not confirm the exact filing date of the US family member corresponding to EP 1 035 115, which is what would determine any § 102(e) exposure.
3. I reviewed only the three citations of record. The "Cited By" list (e.g., US 6,770,637 B2, US 7,288,658 B2, the Helsinn netupitant/fosnetupitant family) is later art and cannot be prior art against this patent.
4. The formula images in claim 1 remain partially garbled in the OCR source; reagent‑level step language should be confirmed against the original drawings at patents.google.com/patent/US6303790B1/en.

I'll ground this obviousness analysis in the actual prior-art references of record on this patent. Let me research each one.

Let me dig into how EP 0235663 and the other family references actually make their 4-aryl pyridines, plus the related Roche filings.

Obviousness Analysis — US 6,303,790 under 35 U.S.C. § 103

Scope note: This analysis builds on the earlier summary/litigation/PTAB sections and does not repeat them. It uses the three references in the Prior Art section of the patent page: EP 0235663 A1 (Warner‑Lambert), EP 1035115 A1 (F. Hoffmann‑La Roche AG), and the non‑patent citation W. Schlecker, A. Huth, E. Ottow, J. Mulzer, Tetrahedron 51(35), 9531–9542 (1995).

⚠️ Contradiction flagged: the earlier sections were generated with "Today's date is 2026‑09‑30"; this task states "Current Date: April 26, 2026." The discrepancy is immaterial here — in either case the patent's 2020‑11‑20 term expiry has passed, so § 103 is being assessed for defensive (past‑damages/invalidity) purposes, not for a live injunction.

⚠️ Date/§ 102 flag (important): The '790 patent is pre‑AIA (filed 2000‑11‑20). Its § 102(b) critical date is the U.S. filing date minus one year = 1999‑11‑20; foreign priority (EP 99123686, 1999‑11‑29) cannot be used to avoid a § 102(b) bar (MPEP 2133). On that basis:

• EP 0235663 A1 (published 1987‑09‑09) — solid § 102(b) art.
• Schlecker 1995 — solid § 102(b) art.
• EP 1035115 A1 (published 2000‑09‑13) — not § 102(a) or (b) art (it post‑dates the 1999‑11‑29 priority and falls inside the one‑year grace). Its U.S. counterpart, US 6,297,375 B1 (Bös et al., granted 2001‑10‑02), was filed ~Feb 2000, i.e. after the '790 invention date, so it is not § 102(e) art unless the '790 claims are denied their 1999 priority. Treat EP 1035115 as (i) the '790 specification's own admitted background art ("It is known that certain 4‑phenyl‑pyridine derivatives can be prepared by the method disclosed in EP1035115") and (ii) motivation/known‑compound evidence — not as § 102 art. The obviousness case therefore rests on Schlecker and EP 0235663, which is where I put the weight below.

1. The level of ordinary skill

A POSITA here is a process/synthetic organic chemist (Ph.D. or M.S. with ~3–5 years in pharmaceutical process R&D) familiar with: nucleophilic addition of organomagnesium reagents to electron‑poor pyridines and pyridinium salts; pyridine ring functionalization (SNAr on 2‑halopyridines); dihydropyridine oxidation/dehydrogenation; the standard carboxamide interconversions (Hofmann/Lossen rearrangement, carbamate formation, hydride reduction, Schotten‑Baumann acylation); and the NK‑1 antagonist literature generally. This is a routine‑skill field; the Court's KSR framework ("combination of familiar elements according to known methods") applies with full force to assigned‑route process claims of this type.

2. The claimed subject matter, reduced to its elements

Claim 1 is a three‑stage process for making a 4‑(R¹)‑pyridine‑3‑carboxamide/3‑acylaminopyridine (formula I):

3. What the prior art actually discloses (grounded)

Schlecker et al. (1995) — the primary reference. Its title is literally "Synthesis of 4‑arylpyridines … via 1,4‑Grignard‑Addition to Pyridinecarboxamides." The abstract states: "2,5‑Pyridinedicarboxamides … and 2,5‑bromo‑3‑pyridinecarboxamide … undergo 1,4‑addition with Grignard reagents to give the 2,4,5‑ or 3,4,5‑ and 2,3,4,5‑substituted pyridines … after oxidation with NCS or oxygen. After selective transformation of amides 5 and 8 to carbamates 17 and 19, a modified intramolecular Goldberg amide arylation furnishes the β‑carbolines…" The body expressly states that "reactions which proceed without prior quaternization of the pyridine nitrogen" include Grignard/lithium addition to pyridine‑3‑carbonyl substrates, that "the addition of ethyl‑ and phenylmagnesium bromide to amide 1 resulted in the clean formation of a single product," and that "quenching of the mixture with a slight excess of MeOH and oxidation with NCS smoothly furnishes the pyridines."
→ Schlecker thus discloses steps (a), (b), and the amide→carbamate transformation underpinning (c′ii), applied to the same scaffold class (4‑arylpyridine bearing a 3‑carboxamide).

EP 0235663 A1 / B1 (Warner‑Lambert, pub. 1987‑09‑09). Discloses 1,2,3,6‑ and 1,2,5,6‑tetrahydro‑pyridine‑3‑carboxylic acids/esters/amides in which "R⁴ = C1‑C6‑alkyl, C2‑C6‑alkenyl, C3‑C8‑cycloalkyl, 2‑ or 3‑thienyl, phenyl, which may be substituted" — i.e., 4‑(aryl/heteroaryl)‑tetrahydropyridine‑3‑carboxamides, the exact intermediate class produced in step (a). Its U.S. counterpart (US 4,745,123) lists species such as "1‑ethyl‑1,2,5,6‑tetrahydro‑N‑methyl‑4‑phenyl‑3‑pyridinecarboxamide" and "4‑(3,4‑dichlorophenyl)‑1‑ethyl‑1,2,5,6‑tetrahydro‑3‑pyridinecarboxylic acid, methyl ester" (freepatentsonline.com/4745123.html).
→ EP 0235663 establishes that 4‑aryl‑dihydro/tetrahydro‑nicotinamide intermediates and their aromatic analogues were a known, pharmaceutically exploited compound class — i.e., the destination of step (a) and the feedstock of step (b).

EP 1035115 A1 (Roche, pub. 2000‑09‑13) / EP 1103545. Discloses the compounds of formula I themselves — including N‑(3,5‑bis‑trifluoromethyl‑benzyl)‑N‑methyl‑6‑(4‑methyl‑piperazin‑1‑yl)‑4‑o‑tolyl‑nicotinamide (claim 5) and 2‑(3,5‑bis‑trifluoromethyl‑phenyl)‑N‑methyl‑N‑(6‑morpholin‑4‑yl‑4‑o‑tolyl‑pyridin‑3‑yl)‑isobutyramide (claim 13) — together with a different route that requires a 4‑halo (Br/I) activating group. Its role here is motivation + admitted background, not § 102.

Additional background (not of record on the '790 face, flagged as such): the N‑[3,5‑bis(trifluoromethyl)benzyl]‑N‑methylcarbamoyl NK‑1 antagonist class (Natsugari et al., J. Med. Chem. 38(16):3106–3120 (1995); Ikeura et al., Chem. Pharm. Bull. 45(10):1642–1652 (1997)) is listed in the EP 1 394 150 B1 search report; I read these only from that citation list, not the full texts. Schultz & Flood, J. Org. Chem. 51:838–841 (1986) and the Comins‑school dihydropyridine literature document the general 1,4‑addition chemistry. These are corroborating, not load‑bearing.

4. Grounds of rejection — combinations and the motivation to combine

Ground 1 — Claim 1 obvious over Schlecker (1995) alone.
Every step is disclosed or is the routine practice of the disclosed step: (a) 1,4‑Grignard addition to a pyridinecarboxamide without N‑quaternization; (b) MeOH quench + oxidation (NCS/O₂) to the aromatic 4‑arylpyridine‑3‑carboxamide; (c′) selective amide→carbamate transformation. Motivation: Schlecker's stated objective is precisely to build 4‑arylpyridine‑3‑carboxamide frameworks convergently; a POSITA making an NK‑1 antagonist nicotinamide (motivated by Natsugari/Ikeura and Roche's own EP 1035115 compounds) would apply Schlecker's route to a 6‑chloro‑ or 6‑amino‑nicotinamide, which are cheap and commercially available. Reasonable expectation of success: Schlecker reports clean, single‑product addition and smooth oxidation; the '790 Examples 1b–1c and 2a confirm the prediction.

Ground 2 — Claim 1 obvious over Schlecker in view of EP 0235663.
EP 0235663 supplies (i) confirmation that the intermediate 4‑aryl‑dihydropyridine‑3‑carboxamides are a known class with known dehydrogenation to the aromatic pyridines, and (ii) the aryl/heteroaryl scope of R⁴/R¹ (phenyl, substituted phenyl, thienyl, C1‑C6 alkyl). Motivation: both references build the same 4‑aryl‑nicotinamide framework; a POSITA seeking an alternative to the halogen‑activated EP 1035115 route would combine Schlecker's addition/oxidation with EP 0235663's demonstration that the resultant tetrahydro species are stable, isolable, pharmaceutically relevant intermediates.

Ground 3 — Claims 1, 15‑dependent (i.e., 2, 4) obvious over Schlecker + routine optimization.
THF as the solvent (claim 2) is Schlecker's own solvent; KHMDS‑mediated N‑benzylation in THF (claim 4) is standard amide/anilide alkylation and is exactly what Roche itself ran (Example 1f).

Ground 4 — Claims 3 (oxidant list).
Schlecker discloses oxidation with NCS/O₂. The recited alternatives — Mn(OAc)₃, Cu(OAc)₂, I₂, Br₂, NBS, Pd/C, Pt/C, DDQ, o‑chloranil, H₂O₂‑urea, MnO₂, KMnO₄, CAN, HNO₃, S — are the art‑recognized, interchangeable dehydrogenation/aromatization reagents for dihydropyridines. Selecting among a small, known set of equivalents with predictable results is not inventive (KSR: "a finite number of identified, predictable solutions"). Notably the '790 Examples themselves use three different oxidants (MnO₂, KMnO₄, Mn(OAc)₃, DDQ, o‑chloranil) in different runs, underscoring interchangeability.

Ground 5 — Claims 6, 7, 8–10, 11, 12 (the c′ii–c′iv sequence).

• Claim 7 (Hofmann rearrangement): a named, textbook reaction since 1881 for converting a primary carboxamide to a primary amine; Schlecker already teaches amide→carbamate; Example 2e (NBS/NaOMe) is the standard Hofmann/Lossen variant.
• Claim 6 (H₂SO₄/AcOH or MsOH cleavage of the N‑tert‑butyl amide to the primary amide): standard acid‑catalyzed amide dealkylation; Example 4d.
• Claims 8–10 (alkyl orthoformate + catalytic acid, then LiAlH₄/NaBH₄/BH₃‑THF/Red‑Al): the archetypal reductive N‑methylation of an aniline.
• Claim 11 (Red‑Al/LiAlH₄ reduction of the carbamate XV → XVI): standard carbamate reduction to N‑methylaniline.
• Claim 12 (tertiary amine base for acylation): textbook Schotten‑Baumann.
  Motivation for the whole (c′) branch: the target molecules of formula I where X = –N(R⁵)C(O)– are the known, more potent NK‑1 antagonists of EP 1103545; a POSITA must invert the 3‑carboxamide into a 3‑methylamino group to reach them, and the Hofmann‑then‑reduce‑then‑acylate sequence is the canonical way to do it.

Ground 6 — Claim 13 (the isobutyramide product).
2‑(3,5‑bis‑trifluoromethyl‑phenyl)‑N‑methyl‑N‑(6‑morpholin‑4‑yl‑4‑o‑tolyl‑pyridin‑3‑yl)‑isobutyramide is a known compound (EP 1103545, same 1999‑11‑29 priority). A process claim covering a known compound is obvious where the process steps are individually and collectively routine; the acid chloride (Example 4g) and the amine (Example 4f) are both known/reachable by the recited steps.

Ground 7 — Claim 14 (XII + VII → VIII).
Displacement of a 2‑halo substituent on a pyridine by an amine is the defining SNAr reaction of the 2‑chloropyridine series and is used in the EP 1035115/EP 1103545 syntheses; the '790 specification itself calls it the "conventional manner."

5. Why a POSITA would have been motivated (consolidated)

1. Stated problem and known target. Roche was developing the same NK‑1 antagonists claimed in its own EP 1035115/EP 1103545; the '790 specification admits those compounds and admits the EP 1035115 halogen‑activation route as the known method. There is an express design need: a shorter, cheaper, scalable synthesis not requiring 4‑halogen activation, PivCl/TMEDA, or organolithium reagents.
2. Schlecker supplies the exact solution. It teaches the 1,4‑Grignard addition on a pyridinecarboxamide without prior quaternization — the very "unexpected" feature the '790 specification relies on — and teaches the subsequent oxidation to the 4‑aryl‑3‑carboxamide.
3. Art‑recognized equivalence of the remaining steps. Dihydropyridine oxidation, Hofmann rearrangement, hydride reduction of carbamates, reductive N‑methylation and acyl chloride acylation are all classic, high‑predictability transformations.
4. No teaching away. The general pyridine literature's α‑(C2) selectivity for Grignards on unactivated pyridines (Schultz/Comins line) is not a teaching away, because Schlecker demonstrates that a 3‑carboxamide directs the addition to the γ‑(C4) position; and a 6‑halo substituent blocks the other α‑position. EP 1035115's halogen‑activation route likewise contains no disparagement of the unactivated route.
5. Predictable, verified result. The '790 Examples show 78–95 % yields on the very first attempts (Ex. 1b 94.6 %; Ex. 1d 78.9 %; Ex. 1e 83.7 %; Ex. 2e quantitative), which is evidence of predictability, not of unexpectedness.

6. Anticipated rebuttals and responses

• "It has surprisingly been found… the reaction is unexpected." (specification, DETAILED DESCRIPTION). This is conclusory and unsupported by comparative data. Schlecker expressly reported non‑quaternized 1,4‑Grignard addition to pyridinecarboxamides four years before the '790 priority date, so the premise of unexpectedness fails on the art of record.
• "The prior art required an activating halogen (Br/I) at C4." That is the applicant's own earlier process (EP 1035115 / schemes 1–2 of '790), not the whole field. Schlecker shows an activation‑free alternative; the existence of one known route requiring activation does not make a second, known activation‑free route nonobvious.
• "The one‑pot step (a′) is unexpected." Running the Grignard addition and the amine displacement in a single vessel is a routine process‑intensification choice for a chemoselective pair of reactions; Example 4c of the same patent shows the two‑step alternative working equally well, undercutting any criticality argument.
• Possible genuine counter‑argument to watch: claim 1's genus breadth (all R¹–R⁶, both X orientations). Schlecker's experimental support covers ethyl and phenyl Grignards on 2,5‑dicarboxamides; alkyl Grignards on other 3‑substituted pyridines were known to be less regioselective (the Schultz/Comins line). A skilled advocate could argue that the full genus — especially R¹ = secondary alkyl (Example 7, i‑PrMgCl; Example 8, p‑F‑C₆H₄MgCl) — was not predictable from Schlecker's two examples alone, requiring the EP 0235663 class disclosure to supply the aryl/heteroaryl breadth. This is a scope argument, not a validity‑saving one for the narrow commercial claims (5, 13).

7. Bottom line

• Claim 1 is prima facie obvious over Schlecker (1995) alone, and a fortiori over Schlecker in view of EP 0235663 — every claimed step (non‑quaternized 1,4‑Grignard addition to a pyridinecarboxamide, oxidative aromatization, and the amide→carbamate interconversion) is disclosed or is the routine working of a disclosed step, and the motivation (make Roche's known NK‑1 antagonist nicotinamides more cheaply) is supplied by the specification's own admission of EP 1035115 and by the known N‑[3,5‑bis(trifluoromethyl)benzyl]‑N‑methylcarboxamide NK‑1 class.
• Claims 2–14, individually, are obvious over Schlecker + EP 0235663 + the ordinary knowledge of a process chemist (Hofmann rearrangement; hydride reductions; Schotten‑Baumann acylation; SNAr with morpholine/N‑methylpiperazine), with EP 1035115/EP 1103545 supplying the motivation to reach the specific products of claims 5 and 13.
• The strongest single reference is Schlecker, not EP 1035115 — and the strongest motivation statement is the '790 specification's own sentence: "It is known that certain 4‑phenyl‑pyridine derivatives can be prepared by the method disclosed in EP1035115."

8. Caveats

1. Formulae are OCR‑garbled in the claim text (e.g., "A denotes R or R⁴"). My element mapping is reconstructed from the specification prose and the legible Examples 1–8, which is reliable, but a formal invalidity contentions chart should be built against the granted drawings at patents.google.com/patent/US6303790/en.
2. I did not read the full EP 0235663 specification — only its abstract, description excerpt, and the US 4,745,123 preferred‑compound list. I assert only that it discloses 4‑aryl‑tetrahydro‑3‑pyridinecarboxamides (a known class), not that it discloses the 1,4‑Grignard route itself. That limitation belongs to Schlecker.
3. I did not read Schlecker's full text; the key quotes above come from the article's abstract/opening pages as retrieved. The passages quoted (no‑quaternization; ethyl/phenyl Grignard addition; MeOH quench + NCS oxidation; amide→carbamate) are the operative ones.
4. § 102 date analysis is my own, from the dates as fetched (EP 0235663 pub. 1987‑09‑09; Schlecker 1995; EP 1035115 pub. 2000‑09‑13; '790 filed 2000‑11‑20). If the '790 claims are denied their 1999‑11‑29 EP priority, US 6,297,375 (filed ~Feb 2000, granted 2001‑10‑02) becomes available as pre‑AIA § 102(e) art, which strengthens rather than weakens the analysis.
5. Ikeura (1997) and Natsugari (1995) are cited here from the EP 1 394 150 B1 search‑report listing only; I did not verify their contents directly. Do not rely on them without checking the originals.
6. The patent is expired (2020‑11‑20); any § 103 invalidity holding here has defensive value only (past damages under § 286), which is consistent with the earlier sections of this analysis.